Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation

Leukemia Research

Volumn 32, Issue 11, 2008, Pages 1783-1786

  Wu, Yi Ying ^a   Hung, Hsiu Man ^a   Chen, Tien Sheng ^a   Chao, Tsu Yi ^a   Ho, Ching Liang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYTARABINE; HYDROXYUREA;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; BASOPHIL; BLAST CELL; BONE MARROW BIOPSY; CASE REPORT; DRUG DOSE REDUCTION; EOSINOPHIL COUNT; FEVER; GENE MUTATION; HUMAN; HUMAN GENOME; HUMAN TISSUE; JANUS KINASE 2 GENE; LETTER; LEUKEMIA; LYMPHOCYTE COUNT; MALE; MEAN CORPUSCULAR VOLUME; MONOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; NEUTROPHIL COUNT; PNEUMONIA; PRIORITY JOURNAL; PROMYELOCYTE; THROMBOCYTE COUNT;

AGED; ALLELES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; LEUKEMIA; MALE; MUTATION; MYELOFIBROSIS; MYELOID METAPLASIA;

EID: 47249118793     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.015     Document Type: Letter

References (20)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues; 2001, p. 32-41.
2. Jelinek J., Oki Y., Gharibyan V., Buesi-Ramos C., Prchal J.T., Verstovsek S., et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukaemia. Blood 106 10 (2005) 3370-3373
3. Royer Y., Staerk J., Costuleanu M., Courtoy P.J., and Constantinescu S.N. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem 280 (2005) 27251-27261
4. Huang L.J., Constantinescu S.N., and Lodish H.F. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 8 (2001) 1327-1338
5. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 134 (2006) 366-384
6. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Laxout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
7. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2 V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110 3 (2005) 840-845
8. Campbell P.J., Griesshammer M., Döhner K., Döhner H., Kusec R., Hasselbalch H.C., et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107 (2006) 2098-2100
9. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadieigh M., et al. MPL515mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006) 3472-3476
10. Cerri M., Lunghi M., Parvis G., Saglio G., Gaidano G., and Cilloni D. JAK2 V617F mutation in leukemic transformation of Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 135 (2006) 267-268
11. Mesa R.A., Powell H., Lasho T., DeWald G., McClure R., and Tefferi A. JAK2 V617F and leukemic transformation in myelofibrosis with myeloid metaplasia. Leukemia Res 30 (2006) 1457-1460
12. Levine R.L., Belisle C., Wadleigh M., Zahrieh D., Lee S., Chagnon P., et al. X-inactivation-based clonality analysis and quantitative JAK2 V617F assessment reveal a strong association between clonality and JAK2 V617F in PV but not ET/MMM, and identifies a subset of JAK2 V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107 10 (2006) 4139-4141
13. Skoda R. Update on the impact of the JAK2 mutation on signaling pathways in myeloproliferative disorders. Eur J Haematol 79 Suppl. 68 (2007) 5-8
14. Tefferi A., Lasho T.L., Schwager S.M., Strand J.S., Elliott M., Mesa R., et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. Cancer 106 3 (2006) 631-635
15. Kittur J., Knudson R.A., Lasho T.L., Finke C.M., Gangat N., Wolanskyj A.P., et al. Clinical correlates of JAK2 V617F allele burden in essential thrombocythemia. Cancer 109 11 (2007) 2279-2284
16. Larsen T.S., Pallisgaard N., Møller M.B., and Hasselbalch H.C. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 79 6 (2007) 508-515
17. Theocharides A., Boissinot M., Girodon F., Garand R., Teo S.S., Lippert E., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110 1 (2007) 375-379
18. Lasho T.L., Paradanani A., McClure R.F., Mesa R.A., Levine R.L., Gilliland D.G., et al. Concurrent MPL515 and JAK2 V617F mutations in myelofibrosis: chronology of clonal emergence and changes n mutant allele burden over time. Br J Haematol 135 (2006) 683-687
19. + cells into peripheral blood in myeloproliferative disorders. Blood 107 9 (2006) 3676-3682
20. Toyama K., Karasawa M., Yokohama A., Saitoh T., Handa H., Matsushima T., et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelet. Br J Haematol 139 (2007) 64-69